Kelun-Biotech Advances TAA-PD-L1 ADC Candidate into China Trials
Event summary
- Kelun-Biotech received Investigational New Drug (IND) approval in China for SKB103, a TAA-PD-L1 bispecific antibody-drug conjugate (bsADC).
- SKB103 is the company’s first TAA-PD-L1 bsADC candidate and the second bsADC program to enter clinical trials, following SKB571.
- The approval was granted by the CDE of the NMPA for the treatment of advanced solid tumors.
- Kelun-Biotech utilizes its proprietary OptiDC™ platform for ADC development.
The big picture
Kelun-Biotech's IND approval for SKB103 underscores the intensifying competition in the oncology ADC space, particularly in China, where regulatory pathways are becoming increasingly streamlined. The company’s focus on dual-mechanism ADCs (TAA-PD-L1) represents a strategic attempt to overcome resistance and improve efficacy compared to single-target therapies. Kelun-Biotech's existing ADC portfolio and OptiDC™ platform provide a foundation for continued innovation, but execution risk remains high given the complexity of ADC development.
What we're watching
- Clinical Efficacy
- The initial clinical trial data for SKB103 will be crucial in validating the preclinical findings and establishing its potential as a best-in-class therapy, particularly given the crowded ADC landscape.
- Regulatory Pathway
- The speed and efficiency of the clinical trial approval process in China will influence the overall timeline for SKB103’s commercialization and Kelun-Biotech’s ability to compete globally.
- Platform Scalability
- The success of SKB103 will hinge on Kelun-Biotech’s ability to leverage its OptiDC™ platform to rapidly advance other ADC and novel DC candidates through the pipeline.
Related topics